Money Concepts Capital Corp Has $11.13 Million Stock Position in Gilead Sciences, Inc. $GILD

Money Concepts Capital Corp lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,857 shares of the biopharmaceutical company’s stock after selling 6,248 shares during the quarter. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $11,130,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GILD. Paulson Wealth Management Inc. lifted its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. increased its stake in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. increased its stake in Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC raised its holdings in Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its holdings in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,000 shares of company stock worth $10,824,500 in the last quarter. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada cut their target price on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday. Truist Financial reduced their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday. Leerink Partners decreased their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Finally, The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $159.04.

Gilead Sciences Price Performance

Shares of GILD stock opened at $134.84 on Friday. The stock’s fifty day simple moving average is $129.76 and its 200 day simple moving average is $134.99. Gilead Sciences, Inc. has a one year low of $107.75 and a one year high of $157.29. The firm has a market cap of $167.41 billion, a price-to-earnings ratio of 18.37 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.